

TABLE OF CONTENTS

ABSTRACT	i
ABSTRACT	iii
ABBREVIATIONS	v
TABLE OF CONTENTS	ix
LIST OF FIGURES	xi
LIST OF TABLES	xii
1. INTRODUCTION	1
1.1 Immune checkpoint blockade in immunotherapy	1
1.1.1 CTLA4	1
1.1.2 PD1/PDL1 pathway	3
1.1.3 Resistance to immune checkpoint blockade	5
1.2 Angiogenesis and its role in immunosuppression	7
1.2.1 VEGFA/VEGFR2 and ANG/TIE2 pathways in angiogenesis	7
1.2.2 The role of angiogenesis in immunosuppression	8
1.3 Lung cancer	10
1.3.1 KRAS signaling in NSCLC	11
1.3.2 Roles of VEGFA and ANG2 in NSCLC	12
1.3.3 Therapies in NSCLC	13
1.3.3.1 Chemotherapy in NSCLC	15
1.3.3.2 Anti-angiogenic therapies in NSCLC	16
1.3.3.3 Immune checkpoint inhibitors in NSCLC	17
1.4 Anti-angiogenic immunotherapy in mouse models of breast cancer	20
1.4.1 A2V provided additive anti-tumoral benefits in an orthotopic MMTV-PyMT breast cancer model	20
1.4.2 A2V impaired tumor angiogenesis and normalized the remaining blood vessels in an orthotopic MMTV-PyMT breast cancer model	21
1.4.3 A2V enhanced extravasation and perivascular accumulation of T cells in an orthotopic MMTV-PyMT breast cancer model	22
1.4.4 Anti-tumoral activity of combined A2V and anti-PD1 therapy in tumor models	23
2. AIMS OF THE THESIS	25
3. RESULTS	27
3.1 Effects of dual blockade of ANG2 and VEGFA by A2V in lung cancer model	27
3.1.1 Characterization of <i>Kras</i> ^{SL-G12D/+} ; <i>p53</i> ^{fl/fl} (KP) mouse model of lung cancer	27
3.1.2 A2V showed significant anti-tumoral activity in KP model of lung cancer	29
3.1.3 A2V decreased vascular density but also reduced pericyte coverage of remaining tumor blood vessels	31
3.1.4 A2V slightly increased tumor-infiltrating CD8 ⁺ T cells but not CD4 ⁺ T cells in KP model	33
3.2 Developing immunogenic lung cancer mouse models	35
3.2.1 Developing and characterizing KP-OVA mouse model of lung cancer	35
3.2.2 Developing and characterizing <i>Kras</i> ^{SL-G12D/+} ; <i>p53</i> ^{fl/fl} ; <i>Msh2</i> ^{fl/fl} (KPM) mouse model of lung cancer	39
3.2.3 A2V provided significant anti-tumoral benefit in KPO and KPM models	41
3.2.4 A2V increased CD8 ⁺ T cell infiltration in immunogenic lung cancer models	42
3.2.5 A2V showed diverse effects on innate immune cells in different lung cancer models	44

3.2.5.1	A2V decreased the relative proportion of antigen-presenting cells but increased antigen presentation	44
3.2.5.2	A2V did not affect neutrophil infiltration in lung tumors	46
3.2.5.3	A2V reduced natural killer cell infiltration in KP tumors but not in KPO and KPM tumors	47
3.2.6	A2V induced a minor increase in PDL1 expression in lung tumor endothelial cells and lung cancer cells	48
3.3	PD1 blockade limited the anti-tumoral activity of dual ANG2 and VEGFA blockade	49
3.3.1	Combination of A2V with PD1 blockade did not improve the therapeutic benefit provided by A2V monotherapy	49
3.3.2	Characterization of T cell infiltration after the combination therapy of A2V and PD1 blockade in lung cancer models	52
3.3.3	A2V plus anti-PD1 therapy did not induce major changes in innate immune cells compared to A2V monotherapy	56
3.3.3.1	Addition of PD1 blockade to A2V decreased antigen presentation compared to A2V monotherapy	56
3.3.3.2	A2V plus anti-PD1 therapy did not affect neutrophil infiltration in lung cancer models	58
3.3.3.3	A2V plus PD1 blockade did not induce changes in neutral killer cell infiltration in lung cancer models	59
3.3.4	Combined A2V and anti-PD1 therapy did not induce a further increase in PDL1 expression in ECs and cancer cells	60
3.3.5	Anti-angiogenic immunotherapy elicited regulatory T cell infiltration in lung tumors, generating an immunosuppressive tumor microenvironment	61
3.4	Inhibition of T _{regs} via CTLA4 blockade worsened the anti-tumoral response of A2V plus anti-PD1 therapy	64
3.4.1	Combined immunotherapies with A2V augmented tumor growth compared to A2V plus anti-PD1 therapy	64
3.4.2	CTLA4 blockade impaired CD8 ⁺ T cell infiltration in the tumors and did not induce changes in myeloid cell compartment	65
3.5	Combination of A2V with PD1 blockade and cisplatin provides important therapeutic benefits	67
4.	DISCUSSION	71
4.1	Effects of dual blockade of ANG2 and VEGFA in orthotopic MMTV-PyMT breast cancer model	71
4.2	Effects of dual blockade of ANG2 and VEGFA and/or PD1 blockade in lung cancer models	72
4.2.1	Effects of dual blockade of VEGFA and ANG2 in mouse models of lung cancer	72
4.2.2	Effects of combination of anti-angiogenics and immune checkpoint blockade in lung cancer models	76
4.2.3	Limitations of mouse models of lung cancer in this study	80
4.3	Conclusions and future directions	82
5.	MATERIALS AND METHODS	85
	REFERENCES	99
	ACKNOWLEDGEMENTS	127
	Curriculum Vitae	129